Can-Fite reports positive Phase 2a data for namodenoson in pancreatic cancer trial
PUBT · 4h ago
Share
Listen to the news
- Can-Fite BioPharma reported positive Phase 2a data for namodenoson in advanced pancreatic cancer.
- Study results have already been presented in part, with full top-line efficacy analyses slated for presentation at a future clinical conference in coming months.
- Trial showed signs of durable disease control in heavily pretreated patients, supporting continued development in pancreatic cancer.
- Can-Fite highlighted extended time on therapy for several patients, with 35% still receiving treatment.
- Safety profile remained favorable, consistent with prior reports.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300831PRIMZONEFULLFEED9710471) on April 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved